NMD Pharma A/S: Financial statements 2023
CVR: 36899069
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR -19,182,079 and a net result of EUR -22,401,436 compared with EUR -12,323,989 the year before. Equity in the 2023 report amounted to EUR 42,672,873. The solvency ratio was 92%. The company had 31 employees in the financial year.
- Gross Profit
- EUR -19,182,079
- Profit/Loss
- EUR -22,401,436
- Equity
- EUR 42,672,873
- Total Assets
- EUR 46,392,625
- Employees
- 31
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -19.2 mio. EUR | -22.4 mio. EUR | 42.7 mio. EUR | 31 |
| 2022 | - | -9.5 mio. EUR | -12.3 mio. EUR | 25.1 mio. EUR | 26 |
| 2021 | - | -11 mio. EUR | -13.6 mio. EUR | 2.6 mio. EUR | 26 |
| 2020 | - | -7.9 mio. EUR | -9.9 mio. EUR | 9.2 mio. EUR | 22 |
| 2019 | - | -7.1 mio. EUR | -8.5 mio. EUR | 140 t. EUR | 17 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 13, 2023, Thomas Holm Pedersen has joined the board of directors of NMD Pharma A/S.
As of October 13, 2023, LUNDBECKFOND INVEST A/S is registered as an owner of NMD Pharma A/S with an ownership share of 15%.
As of October 13, 2023, Novo Holdings A/S is registered as an owner of NMD Pharma A/S with an ownership share of 15%.
NMD Pharma A/S has published its annual report for 2022. Gross profit came to DKK -9,480,436, and the net result was DKK -12,323,989.
As of May 1, 2023, Simone Botti has joined the board of directors of NMD Pharma A/S.
As of May 1, 2023, Roel Bulthuis has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.